Phase 3 N=156 Lubiprostone for Treatment of Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.1; 4.4 SBMs/week — p=0.007
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=9 Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
Hepatitis C
Primary: Percentage of Participants Experiencing an Adverse Event (AE) — 66.7; 66.7; 33.3 Percentage of Participants
Phase 1 N=24 Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females
Healthy
Primary: Steady-State Concentration (Css) (48-168) Profile for LNG — 1256; 1246; 1384 pg/mL
Phase 3 N=619 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Trough FEV1 on Day 85 — 59.81; 126.85; -19.41 mL
Phase 2 N=55 A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) on Day 8 — 17.83; 19.15; 19.59; 17.51 mm Hg
N/A N=112 Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
Intractable Chronic Migraine
Primary: Adverse Events (First 12 Weeks) — 17; 27; 5; 1 events
N/A N=40 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 100 percentage of participants
Phase 3 N=611 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Trough FEV1 on Day 85 — 115.58; 102.90; -44.92 mL
Phase 4 N=36 Impact of Combined Hormonal Contraceptives on UPA
Contraception
Primary: Number of Participants With Follicle Rupture — 1; 9 Participants
Phase 3 N=137 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.01; -7.5 units on a scale
N/A N=107 Anaemetro I.V. Infusion 500mg Drug Use Investigation
Anaerobic Infection · Infectious Enterocolitis · Amebic Dysentery
Primary: Number of Participants With Adverse Drug Reaction (ADR) — 7; 1 Participants
Phase 1 N=159 A Family-based, Resilience-focused Intervention for War-affected Communities in North-eastern Democratic Republic of Congo
Psychological Distress
Primary: Reduction in Post-traumatic Stress Reaction Symptoms Among Participants — 11.79; 11.80; 12.17; 10.03 units on a scale
Phase 3 N=176 HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
Malaria · HIV Infections
Primary: Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk. — 1.32; 2.25 Episodes/ Person-Yr at Risk — p=0.04
Phase 2 N=32 Gulf War Illness: Evaluation of an Innovative Detoxification Program
Gulf War Illness
Primary: Short Form-36 for Veterans Quality of Life Physical Component Summary Scores — 30.3; 36.7; 38.2; 35.7 score on a scale — p=<0.05
N/A N=20 Adjusting Insulin Delivery to Activity
Diabetes · Nocturnal Hypoglycemia
Primary: Change From Baseline in Supplemental Carbohydrate Interventions up to 3 Months From Baseline. — 0.11 Supplemental Carb (SC) admin. per night